|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schrader AJ, Varga Z, Hegele A, Pfoertner
S, Olbert P and Hofmann R: Second-line strategies for metastatic
renal cell carcinoma: Classics and novel approaches. J Cancer Res
Clin Oncol. 132:137–149. 2006. View Article : Google Scholar
|
|
3
|
Vogelzang NJ and Stadler WM: Kidney
cancer. Lancet. 352:1691–1696. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang L, Yu SY and Hu GY: Pituitary
metastasis from a renal cell carcinoma progressed after sorafenib
treatment. Chin J Cancer. 32:353–356. 2013. View Article : Google Scholar :
|
|
6
|
Zhang ZL, Li YH, Xiong YH, Hou GL, Yao K,
Dong P, Liu ZW, Han H, Qin ZK and Zhou FJ: Oncological outcome of
surgical treatment in 336 patients with renal cell carcinoma. Chin
J Cancer. 29:995–999. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Majid S, Saini S and Dahiya R: Wnt
signaling pathways in urological cancers: Past decades and still
growing. Mol Cancer. 11:72012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sjölund J, Johansson M, Manna S, Norin C,
Pietras A, Beckman S, Nilsson E, Ljungberg B and Axelson H:
Suppression of renal cell carcinoma growth by inhibition of Notch
signaling in vitro and in vivo. J Clin Invest. 118:217–228. 2008.
View Article : Google Scholar
|
|
9
|
Artavanis-Tsakonas S, Rand MD and Lake RJ:
Notch signaling: Cell fate control and signal integration in
development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iso T, Kedes L and Hamamori Y: HES and
HERP families: Multiple effectors of the Notch signaling pathway. J
Cell Physiol. 194:237–255. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ai Q, Ma X, Huang Q, Liu S, Shi T, Zhang
C, Zhu M, Zhang Y, Wang B, Ni D, et al: High-level expression of
Notch1 increased the risk of metastasis in T1 stage clear cell
renal cell carcinoma. PLoS One. 7:e350222012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu K, Zhang L, Lin Y, Yang K and Cheng Y:
Inhibition of γ-secretase induces G2/M arrest and triggers
apoptosis in renal cell carcinoma. Oncol Lett. 8:55–61.
2014.PubMed/NCBI
|
|
13
|
Wu K, Xu L, Zhang L, Lin Z and Hou J: High
Jagged1 expression predicts poor outcome in clear cell renal cell
carcinoma. Jpn J Clin Oncol. 41:411–416. 2011. View Article : Google Scholar
|
|
14
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ljungberg B, Campbell SC, Choi HY, Jacqmin
D, Lee JE, Weikert S and Kiemeney LA: The epidemiology of renal
cell carcinoma. Eur Urol. 60:615–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al TARGET Study Group: Sorafenib in advanced clear-cell
renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rasul S, Balasubramanian R, Filipović A,
Slade MJ, Yagüe E and Coombes RC: Inhibition of gamma-secretase
induces G2/M arrest and triggers apoptosis in breast cancer cells.
Br J Cancer. 100:1879–1888. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wei P, Walls M, Qiu M, Ding R, Denlinger
RH, Wong A, Tsaparikos K, Jani JP, Hosea N, Sands M, et al:
Evaluation of selective gamma-secretase inhibitor PF-03084014 for
its antitumor efficacy and gastrointestinal safety to guide optimal
clinical trial design. Mol Cancer Ther. 9:1618–1628. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hellström M, Phng LK, Hofmann JJ, Wallgard
E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N,
et al: Dll4 signalling through Notch1 regulates formation of tip
cells during angiogenesis. Nature. 445:776–780. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qi R, An H, Yu Y, Zhang M, Liu S, Xu H,
Guo Z, Cheng T and Cao X: Notch1 signaling inhibits growth of human
hepatocellular carcinoma through induction of cell cycle arrest and
apoptosis. Cancer Res. 63:8323–8329. 2003.PubMed/NCBI
|
|
21
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang Q, Zhang Y, Beezhold KJ, Bhatia D,
Zhao H, Chen J, Castranova V, Shi X and Chen F: Sustained JNK1
activation is associated with altered histone H3 methylations in
human liver cancer. J Hepatol. 50:323–333. 2009. View Article : Google Scholar
|
|
23
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu J and Lin A: Role of JNK activation in
apoptosis: A double-edged sword. Cell Res. 15:36–42. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barbarulo A, Iansante V, Chaidos A, Naresh
K, Rahemtulla A, Franzoso G, Karadimitris A, Haskard DO, Papa S and
Bubici C: Poly(ADP-ribose) polymerase family member 14 (PARP14) is
a novel effector of the JNK2-dependent pro-survival signal in
multiple myeloma. Oncogene. 32:4231–4242. 2013. View Article : Google Scholar
|
|
26
|
Hui L, Zatloukal K, Scheuch H, Stepniak E
and Wagner EF: Proliferation of human HCC cells and chemically
induced mouse liver cancers requires JNK1-dependent p21
downregulation. J Clin Invest. 118:3943–3953. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
del Barco Barrantes I and Nebreda AR:
Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans.
40:79–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim ES, Kim MS and Moon A: TGF-β-induced
upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK
signaling in MCF10A human breast epithelial cells. Int J Oncol.
25:1375–1382. 2004.PubMed/NCBI
|
|
29
|
Kumar B, Koul S, Petersen J, Khandrika L,
Hwa JS, Meacham RB, Wilson S and Koul HK: p38 mitogen-activated
protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer
by modulation of MMP-2 and MMP-9 activity. Cancer Res. 70:832–841.
2010. View Article : Google Scholar : PubMed/NCBI
|
